Expression of vascular endothelial growth factor receptors in human prostate cancer.
暂无分享,去创建一个
P C Albertsen | V. Laudone | L. Miller | P. Albertsen | F. Ferrer | D. Kreutzer | F A Ferrer | V P Laudone | L J Miller | R Lindquist | P Kowalczyk | D L Kreutzer | P. Kowalczyk | P. Kowalczyk | R. Lindquist | V. Laudone | Peter C. Albertsen | P. Albertsen
[1] M. Shibuya,et al. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. , 1994, The Journal of biological chemistry.
[2] M. Brawer,et al. Comparison of microscopic vascularity in benign and malignant prostate tissue. , 1993, Human pathology.
[3] R. Masood,et al. Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[4] V. Laudone,et al. Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells. , 1997, The Journal of urology.
[5] M. Shibuya,et al. A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF. , 1995, Oncogene.
[6] M. Waxham,et al. Interaction of the Flt-1 Tyrosine Kinase Receptor with the p85 Subunit of Phosphatidylinositol 3-Kinase , 1995, The Journal of Biological Chemistry.
[7] R. Warren,et al. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. , 1995, The Journal of clinical investigation.
[8] E. Manseau,et al. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. , 1993, The American journal of pathology.
[9] L. Ellis,et al. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. , 1995, Cancer research.
[10] W Blumenfeld,et al. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. , 1993, The American journal of pathology.
[11] D. Kerr,et al. Melanoma cell lines express VEGF receptor KDR and respond to exogenously added VEGF. , 1995, Biochemical and biophysical research communications.
[12] I. Takanami,et al. Vascular endothelial growth factor and its receptor correlate with angiogenesis and survival in pulmonary adenocarcinoma. , 1997, Anticancer research.
[13] A. Ullrich,et al. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant , 1994, Nature.
[14] B. Terman,et al. Biological activity and phosphorylation sites of the bacterially expressed cytosolic domain of the KDR VEGF-receptor. , 1994, Biochemical and biophysical research communications.
[15] D. Charnock-Jones,et al. Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. , 1995, Journal of the National Cancer Institute.
[16] H. Dvorak,et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. , 1995, The American journal of pathology.
[17] D. Rose,et al. Angiogenesis in two human prostate cancer cell lines with differing metastatic potential when growing as solid tumors in nude mice. , 1998, The Journal of urology.
[18] S. Chevalier. Commentary on prostatic neovascularization and vascular endothelial growth factor. , 1997, The Journal of urology.
[19] J. Folkman. Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.
[20] Bing Li,et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo , 1993, Nature.